Stem definition | Drug id | CAS RN |
---|---|---|
diazepam derivatives | 1802 | 59467-70-8 |
Dose | Unit | Route |
---|---|---|
15 | mg | O |
15 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 10.30 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 5.60 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.26 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 44 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.10 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 3.10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 20, 1985 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 579.54 | 60.10 | 257 | 1605 | 101367 | 2254856 |
Hypotension | 444.92 | 60.10 | 156 | 1706 | 32280 | 2323943 |
Cardiac arrest | 307.88 | 60.10 | 98 | 1764 | 14832 | 2341391 |
Anaphylactic reaction | 299.81 | 60.10 | 87 | 1775 | 9618 | 2346605 |
Status epilepticus | 212.05 | 60.10 | 50 | 1812 | 2428 | 2353795 |
Toxicity to various agents | 196.38 | 60.10 | 87 | 1775 | 32667 | 2323556 |
Tachycardia | 186.13 | 60.10 | 69 | 1793 | 16340 | 2339883 |
Oxygen saturation decreased | 186.04 | 60.10 | 57 | 1805 | 7529 | 2348694 |
Unresponsive to stimuli | 160.34 | 60.10 | 46 | 1816 | 4830 | 2351393 |
Drug interaction | 154.05 | 60.10 | 71 | 1791 | 29092 | 2327131 |
Bradycardia | 147.05 | 60.10 | 51 | 1811 | 9930 | 2346293 |
Seizure | 143.15 | 60.10 | 64 | 1798 | 24402 | 2331821 |
Exposure during pregnancy | 134.96 | 60.10 | 62 | 1800 | 25157 | 2331066 |
Anaphylactic shock | 134.47 | 60.10 | 39 | 1823 | 4247 | 2351976 |
Agitation | 130.74 | 60.10 | 48 | 1814 | 11003 | 2345220 |
Intestinal ischaemia | 114.40 | 60.10 | 26 | 1836 | 1065 | 2355158 |
Multiple organ dysfunction syndrome | 112.28 | 60.10 | 39 | 1823 | 7602 | 2348621 |
Respiratory failure | 110.86 | 60.10 | 45 | 1817 | 13483 | 2342740 |
Circulatory collapse | 108.50 | 60.10 | 32 | 1830 | 3688 | 2352535 |
Hypoxia | 108.01 | 60.10 | 36 | 1826 | 6191 | 2350032 |
Respiratory depression | 106.15 | 60.10 | 28 | 1834 | 2142 | 2354081 |
Generalised tonic-clonic seizure | 100.95 | 60.10 | 33 | 1829 | 5339 | 2350884 |
Maternal exposure during pregnancy | 96.83 | 60.10 | 42 | 1820 | 14821 | 2341402 |
Delirium | 93.77 | 60.10 | 31 | 1831 | 5192 | 2351031 |
Serotonin syndrome | 88.31 | 60.10 | 27 | 1835 | 3513 | 2352710 |
Labile blood pressure | 87.94 | 60.10 | 16 | 1846 | 207 | 2356016 |
Propofol infusion syndrome | 84.46 | 60.10 | 14 | 1848 | 100 | 2356123 |
Anaesthetic complication neurological | 84.36 | 60.10 | 12 | 1850 | 24 | 2356199 |
Bronchospasm | 83.74 | 60.10 | 25 | 1837 | 2999 | 2353224 |
Respiratory acidosis | 83.01 | 60.10 | 19 | 1843 | 802 | 2355421 |
Completed suicide | 82.90 | 60.10 | 42 | 1820 | 20992 | 2335231 |
Shock | 80.91 | 60.10 | 26 | 1836 | 3978 | 2352245 |
Cardiogenic shock | 79.54 | 60.10 | 23 | 1839 | 2468 | 2353755 |
Loss of consciousness | 78.42 | 60.10 | 39 | 1823 | 18728 | 2337495 |
Apnoea | 77.64 | 60.10 | 20 | 1842 | 1391 | 2354832 |
Sedation | 76.91 | 60.10 | 24 | 1838 | 3338 | 2352885 |
Anaesthetic complication | 76.56 | 60.10 | 16 | 1846 | 439 | 2355784 |
Mitochondrial DNULL mutation | 75.98 | 60.10 | 10 | 1852 | 7 | 2356216 |
Myoclonus | 75.18 | 60.10 | 22 | 1840 | 2461 | 2353762 |
Upper airway obstruction | 73.98 | 60.10 | 13 | 1849 | 136 | 2356087 |
Drug abuse | 71.84 | 60.10 | 32 | 1830 | 11994 | 2344229 |
Foetal death | 71.62 | 60.10 | 20 | 1842 | 1892 | 2354331 |
Diabetic macroangiopathy | 71.34 | 60.10 | 9 | 1853 | 2 | 2356221 |
Delayed recovery from anaesthesia | 70.69 | 60.10 | 13 | 1849 | 179 | 2356044 |
Cardio-respiratory arrest | 69.98 | 60.10 | 29 | 1833 | 9117 | 2347106 |
Intra-abdominal pressure increased | 69.97 | 60.10 | 10 | 1852 | 21 | 2356202 |
Respiratory arrest | 69.87 | 60.10 | 26 | 1836 | 6152 | 2350071 |
Sinus tachycardia | 68.85 | 60.10 | 22 | 1840 | 3303 | 2352920 |
Electrocardiogram ST segment depression | 67.13 | 60.10 | 15 | 1847 | 567 | 2355656 |
Procedural complication | 66.91 | 60.10 | 17 | 1845 | 1118 | 2355105 |
Foetal growth restriction | 66.84 | 60.10 | 17 | 1845 | 1123 | 2355100 |
Pneumatosis | 66.67 | 60.10 | 11 | 1851 | 76 | 2356147 |
Blood pressure decreased | 66.35 | 60.10 | 28 | 1834 | 9208 | 2347015 |
Encephalopathy | 65.85 | 60.10 | 23 | 1839 | 4538 | 2351685 |
Somnolence | 64.75 | 60.10 | 37 | 1825 | 23448 | 2332775 |
Anaesthetic complication pulmonary | 63.96 | 60.10 | 9 | 1853 | 16 | 2356207 |
Unwanted awareness during anaesthesia | 63.71 | 60.10 | 10 | 1852 | 48 | 2356175 |
Systemic inflammatory response syndrome | 62.74 | 60.10 | 15 | 1847 | 766 | 2355457 |
Diabetes insipidus | 61.91 | 60.10 | 13 | 1849 | 365 | 2355858 |
Blood lactic acid increased | 61.46 | 60.10 | 15 | 1847 | 836 | 2355387 |
Kounis syndrome | 60.57 | 60.10 | 12 | 1850 | 250 | 2355973 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hypotension | 456.06 | 51.49 | 177 | 1687 | 29477 | 1715440 |
Drug ineffective | 383.80 | 51.49 | 197 | 1667 | 63604 | 1681313 |
Anaphylactic reaction | 283.03 | 51.49 | 84 | 1780 | 6029 | 1738888 |
Toxicity to various agents | 261.16 | 51.49 | 119 | 1745 | 29022 | 1715895 |
Sedation | 249.01 | 51.49 | 67 | 1797 | 3350 | 1741567 |
Respiratory depression | 221.29 | 51.49 | 56 | 1808 | 2191 | 1742726 |
Oxygen saturation decreased | 198.67 | 51.49 | 63 | 1801 | 5612 | 1739305 |
Cardiac arrest | 180.64 | 51.49 | 77 | 1787 | 15853 | 1729064 |
Coma | 171.76 | 51.49 | 60 | 1804 | 7202 | 1737715 |
Status epilepticus | 167.29 | 51.49 | 44 | 1820 | 2002 | 1742915 |
Tachycardia | 166.46 | 51.49 | 68 | 1796 | 12560 | 1732357 |
Seizure | 165.31 | 51.49 | 78 | 1786 | 20363 | 1724554 |
Bradycardia | 164.09 | 51.49 | 64 | 1800 | 10470 | 1734447 |
Respiratory arrest | 156.51 | 51.49 | 53 | 1811 | 5786 | 1739131 |
Drug abuse | 138.08 | 51.49 | 61 | 1803 | 13628 | 1731289 |
Agitation | 130.39 | 51.49 | 55 | 1809 | 10971 | 1733946 |
Hyperthermia malignant | 126.33 | 51.49 | 25 | 1839 | 304 | 1744613 |
Respiratory failure | 122.10 | 51.49 | 57 | 1807 | 14448 | 1730469 |
Delirium | 118.13 | 51.49 | 44 | 1820 | 6318 | 1738599 |
Cardio-respiratory arrest | 115.32 | 51.49 | 48 | 1816 | 9245 | 1735672 |
Unresponsive to stimuli | 108.33 | 51.49 | 38 | 1826 | 4591 | 1740326 |
Anaesthetic complication neurological | 100.45 | 51.49 | 15 | 1849 | 23 | 1744894 |
Anaphylactic shock | 96.35 | 51.49 | 31 | 1833 | 2868 | 1742049 |
Pulseless electrical activity | 93.26 | 51.49 | 24 | 1840 | 996 | 1743921 |
Dyskinesia | 91.81 | 51.49 | 32 | 1832 | 3787 | 1741130 |
Metabolic acidosis | 91.66 | 51.49 | 35 | 1829 | 5367 | 1739550 |
Drug reaction with eosinophilia and systemic symptoms | 90.18 | 51.49 | 34 | 1830 | 5036 | 1739881 |
Blood pressure decreased | 89.79 | 51.49 | 38 | 1826 | 7608 | 1737309 |
Procedural complication | 86.35 | 51.49 | 23 | 1841 | 1093 | 1743824 |
Rhabdomyolysis | 85.28 | 51.49 | 41 | 1823 | 11049 | 1733868 |
Depressed level of consciousness | 84.91 | 51.49 | 35 | 1829 | 6557 | 1738360 |
Circulatory collapse | 83.13 | 51.49 | 29 | 1835 | 3438 | 1741479 |
Somnolence | 82.85 | 51.49 | 46 | 1818 | 16693 | 1728224 |
Hyperthermia | 81.25 | 51.49 | 24 | 1840 | 1667 | 1743250 |
Acidosis hyperchloraemic | 78.83 | 51.49 | 13 | 1851 | 49 | 1744868 |
Hypoxia | 74.54 | 51.49 | 31 | 1833 | 5932 | 1738985 |
Apnoea | 71.51 | 51.49 | 21 | 1843 | 1428 | 1743489 |
Confusional state | 70.11 | 51.49 | 45 | 1819 | 21233 | 1723684 |
Diabetes insipidus | 64.40 | 51.49 | 15 | 1849 | 407 | 1744510 |
Intestinal ischaemia | 64.22 | 51.49 | 18 | 1846 | 1035 | 1743882 |
Neonatal respiratory depression | 62.77 | 51.49 | 11 | 1853 | 64 | 1744853 |
Mental status changes | 60.82 | 51.49 | 27 | 1837 | 6048 | 1738869 |
Product administered to patient of inappropriate age | 59.17 | 51.49 | 16 | 1848 | 804 | 1744113 |
Post procedural complication | 57.38 | 51.49 | 20 | 1844 | 2360 | 1742557 |
Drug interaction | 56.80 | 51.49 | 44 | 1820 | 27914 | 1717003 |
Aggression | 56.31 | 51.49 | 28 | 1836 | 8087 | 1736830 |
Rash maculo-papular | 55.69 | 51.49 | 22 | 1842 | 3681 | 1741236 |
Hypoventilation | 55.53 | 51.49 | 14 | 1850 | 533 | 1744384 |
Ventricular fibrillation | 54.51 | 51.49 | 20 | 1844 | 2736 | 1742181 |
Overdose | 54.16 | 51.49 | 35 | 1829 | 16666 | 1728251 |
Respiratory distress | 51.86 | 51.49 | 23 | 1841 | 5134 | 1739783 |
Source | Code | Description |
---|---|---|
ATC | N05CD08 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives |
MeSH PA | D000759 | Adjuvants, Anesthesia |
FDA EPC | N0000175694 | Benzodiazepine |
FDA CS | M0002356 | Benzodiazepines |
MeSH PA | D000777 | Anesthetics |
MeSH PA | D018686 | Anesthetics, Intravenous |
CHEBI has role | CHEBI:91016 | GABAA receptor agonist |
CHEBI has role | CHEBI:35623 | anticonvulsant |
CHEBI has role | CHEBI:35474 | anxiolytic drug |
CHEBI has role | CHEBI:35610 | antineoplastic agent |
CHEBI has role | CHEBI:51371 | muscle relaxant |
CHEBI has role | CHEBI:35717 | sedative |
CHEBI has role | CHEBI:38869 | general anaesthetic |
CHEBI has role | CHEBI:35488 | central nervous system depressant |
MeSH PA | D014151 | Anti-Anxiety Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D018682 | GABA Agents |
MeSH PA | D018757 | GABA Modulators |
MeSH PA | D006993 | Hypnotics and Sedatives |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Feeling agitated | indication | 24199005 | |
Anxiety | indication | 48694002 | |
General anesthesia | indication | 50697003 | |
Sedation | indication | 72641008 | |
Conscious sedation | indication | 314271007 | |
Local anesthesia | indication | 386761002 | |
Induce Anterograde Amnesia | indication | ||
Sedation in Intubated Patients | indication | ||
Preoperative Anxiety | indication | ||
Sedation as Adjunct to Anesthesia | indication | ||
Insomnia | off-label use | 193462001 | |
Status epilepticus | off-label use | 230456007 | DOID:1824 |
Cocaine-Associated Acute Ischemic Heart Disease | off-label use | ||
Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
Shock | contraindication | 27942005 | |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Chronic heart failure | contraindication | 48447003 | |
Pregnancy, function | contraindication | 289908002 | |
Coma | contraindication | 371632003 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Hemodynamic instability | contraindication | 422773005 | |
Peripheral Vasoconstriction | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.07 | Basic |
pKa2 | 2.36 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
5MG/SPRAY | NAYZILAM | UCB INC | N211321 | May 17, 2019 | RX | SPRAY | NASAL | 8217033 | Jan. 18, 2028 | ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER |
5MG/SPRAY | NAYZILAM | UCB INC | N211321 | May 17, 2019 | RX | SPRAY | NASAL | 9289432 | Jan. 18, 2028 | ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER |
5MG/SPRAY | NAYZILAM | UCB INC | N211321 | May 17, 2019 | RX | SPRAY | NASAL | 9687495 | Jan. 18, 2028 | ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
5MG/SPRAY | NAYZILAM | UCB INC | N211321 | May 17, 2019 | RX | SPRAY | NASAL | May 21, 2022 | NEW PRODUCT |
EQ 50MG BASE/10ML (EQ 5MG BASE/ML) | SEIZALAM | MERIDIAN MEDCL TECHN | N209566 | Sept. 14, 2018 | RX | SOLUTION | INTRAMUSCULAR | Sept. 14, 2025 | TREATMENT OF STATUS EPILEPTICUS IN ADULTS |
5MG/SPRAY | NAYZILAM | UCB INC | N211321 | May 17, 2019 | RX | SPRAY | NASAL | May 17, 2026 | ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
GABA-A receptor alpha-1/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.74 | WOMBAT-PK | CHEMBL | |||
GABA A receptor alpha-3/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.44 | WOMBAT-PK | CHEMBL | |||
GABA A receptor alpha-5/beta-3/gamma-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.26 | WOMBAT-PK | CHEMBL | |||
GABA-A receptor alpha-5/beta-3/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 9.12 | WOMBAT-PK | CHEMBL | |||
GABA A receptor alpha-3/beta-2/gamma-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 7.61 | WOMBAT-PK | CHEMBL | |||
GABA-A receptor alpha-1/beta-2/gamma-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 7.75 | WOMBAT-PK | CHEMBL | |||
GABA A receptor alpha-5/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 9.12 | WOMBAT-PK | CHEMBL | |||
GABA A receptor alpha-5/beta-2/gamma-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.26 | WOMBAT-PK | CHEMBL | |||
Multidrug resistance protein 1 | Transporter | Km | 4.35 | WOMBAT-PK | |||||
Cytochrome P450 3A4 | Enzyme | Km | 6 | WOMBAT-PK | |||||
Thyrotropin-releasing hormone receptor | GPCR | ANTAGONIST | Ki | 5.49 | IUPHAR | ||||
GABA-A receptor; anion channel | Ion channel | Ki | 8.70 | CHEMBL | |||||
Translocator protein | Membrane receptor | Ki | 8.70 | CHEMBL |
ID | Source |
---|---|
4019839 | VUID |
N0000147927 | NUI |
C0026056 | UMLSCUI |
D00550 | KEGG_DRUG |
26800000 | SNOMEDCT_US |
4019839 | VANDF |
6960 | RXNORM |
373476007 | SNOMEDCT_US |
d00301 | MMSL |
130935 | MMSL |
24970 | MMSL |
004585 | NDDF |
CHEMBL655 | ChEMBL_ID |
DB00683 | DRUGBANK_ID |
CHEMBL1200420 | ChEMBL_ID |
R60L0SM5BC | UNII |
4497 | INN_ID |
08J | PDB_CHEM_ID |
CHEBI:6931 | CHEBI |
59467-96-8 | SECONDARY_CAS_RN |
4192 | PUBCHEM_CID |
D008874 | MESH_DESCRIPTOR_UI |
3342 | IUPHAR_LIGAND_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-3566 | SYRUP | 2 mg | ORAL | ANDA | 14 sections |
MIDAZOLAM HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2305 | INJECTION, SOLUTION | 1 mg | INTRAMUSCULAR | ANDA | 15 sections |
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2306 | INJECTION, SOLUTION | 1 mg | INTRAMUSCULAR | ANDA | 15 sections |
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2307 | INJECTION, SOLUTION | 5 mg | INTRAMUSCULAR | ANDA | 15 sections |
MIDAZOLAM HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2308 | INJECTION, SOLUTION | 5 mg | INTRAMUSCULAR | ANDA | 15 sections |
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2587 | INJECTION, SOLUTION | 1 mg | INTRAMUSCULAR | ANDA | 15 sections |
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2596 | INJECTION, SOLUTION | 5 mg | INTRAMUSCULAR | ANDA | 15 sections |
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0150 | SYRUP | 2 mg | ORAL | ANDA | 15 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6056 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6057 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6059 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6060 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6061 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6063 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6190 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 15 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6209 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6210 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6211 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 16 sections |
Seizalam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 11704-650 | INJECTION, SOLUTION | 5 mg | INTRAMUSCULAR | NDA | 18 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-523 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 15 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-524 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 15 sections |
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0146 | SYRUP | 2 mg | ORAL | ANDA | 15 sections |
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0205 | SYRUP | 2 mg | ORAL | ANDA | 12 sections |
Midazolam Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-3566 | SYRUP | 2 mg | ORAL | ANDA | 13 sections |
Midazolam hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-600 | INJECTION, SOLUTION | 1 mg | INTRAMUSCULAR | ANDA | 14 sections |
Midazolam hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-601 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 14 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47781-588 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | ANDA | 15 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47781-589 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 15 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0683 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 16 sections |
Midazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0738 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 16 sections |